ELEDON PHARMACEUTICALS INC (ELDN)

US28617K1016 - Common Stock

4.075  +0 (+0.12%)

Fundamental Rating

1

Taking everything into account, ELDN scores 1 out of 10 in our fundamental rating. ELDN was compared to 565 industry peers in the Biotechnology industry. ELDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ELDN has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ELDN had negative earnings in the past year.
In the past year ELDN has reported a negative cash flow from operations.
In the past 5 years ELDN always reported negative net income.
ELDN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ELDN has a Return On Assets of -73.47%. This is in the lower half of the industry: ELDN underperforms 68.27% of its industry peers.
Industry RankSector Rank
ROA -73.47%
ROE N/A
ROIC N/A
ROA(3y)-53.44%
ROA(5y)-63.75%
ROE(3y)-57.95%
ROE(5y)-70.87%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ELDN has more shares outstanding
The number of shares outstanding for ELDN has been increased compared to 5 years ago.
ELDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ELDN has an Altman-Z score of -3.85. This is a bad value and indicates that ELDN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.85, ELDN perfoms like the industry average, outperforming 43.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.85
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ELDN has a Current Ratio of 14.48. This indicates that ELDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 14.48, ELDN belongs to the top of the industry, outperforming 88.77% of the companies in the same industry.
ELDN has a Quick Ratio of 14.48. This indicates that ELDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 14.48, ELDN belongs to the top of the industry, outperforming 88.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.48
Quick Ratio 14.48

More info and screens

1

3. Growth

3.1 Past

ELDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.22%, which is quite good.
EPS 1Y (TTM)8.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.25%
EPS Next 2Y14.6%
EPS Next 3Y15.3%
EPS Next 5Y8.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELDN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ELDN's earnings are expected to grow with 15.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.6%
EPS Next 3Y15.3%

More info and screens

0

5. Dividend

5.1 Amount

ELDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (11/22/2024, 10:00:03 AM)

4.075

+0 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap243.44M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.47%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 14.48
Quick Ratio 14.48
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)8.22%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y11.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y